Ideal Serum Uric Acid Target in Uric Acid Stone Formers

Primary Target: Below 6 mg/dL

• The American College of Rheumatology recommends maintaining serum uric acid below 6 mg/dL (360 µmol/L) to prevent crystal formation and promote dissolution of existing crystals in patients with uric acid kidney stones 1, 2, 3, 4
• The European League Against Rheumatism suggests that this target applies to all patients with uric acid stones and should be maintained lifelong 1, 2

Lower Target for Severe Disease: Below 5 mg/dL

• For patients with severe manifestations, such as recurrent stones or large stone burden, the American College of Rheumatology recommends targeting serum uric acid <5 mg/dL (300 µmol/L) until complete crystal dissolution occurs 1, 2, 5, 6
• The velocity of crystal dissolution is directly proportional to how far below saturation the serum uric acid level is maintained, according to the European League Against Rheumatism 1, 2

Avoid Excessive Lowering: Not Below 3 mg/dL Long-Term

• The American College of Rheumatology advises against maintaining serum uric acid <3 mg/dL chronically, as emerging evidence suggests potential neurodegenerative risks and other adverse effects from extreme hypouricemia 1, 2

Practical Treatment Algorithm

• The European League Against Rheumatism recommends monitoring serum uric acid regularly during titration and ensuring adequate hydration and urine alkalinization 1, 5

Renal Impairment Adjustments

• For patients with creatinine clearance 10-20 mL/min, the American College of Rheumatology recommends a maximum allopurinol dose of 200 mg daily 1
• For patients with creatinine clearance <10 mL/min, the European League Against Rheumatism suggests a maximum allopurinol dose of 100 mg daily 1

Critical Pitfalls to Avoid

• The American College of Rheumatology advises against relying on serum uric acid for diagnosis, as levels may be normal during acute stone episodes due to negative acute-phase reactant behavior 7
• The European League Against Rheumatism recommends against stopping therapy once target is reached, as approximately 40% of patients experience recurrence after withdrawal 1, 2

Monitoring Strategy

• The American College of Rheumatology recommends measuring serum uric acid regularly during dose titration and once stable, continuing periodic monitoring to ensure sustained target achievement 1, 2, 5, 6
• The European League Against Rheumatism suggests monitoring renal function at diagnosis and regularly thereafter 5, 6